|
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical research trials and Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies  Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
For Condition: Lymphoma,Wilms' Tumor,Leukemia,Soft Tissue Sarcoma,Osteosarcoma
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The goal of this clinical research study is to learn if treatment with the drug liposomal vincristine can shrink or slow the growth of the patient's cancer. The safety of this drug will also be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with relapsed malignancies in the following strata: (As of 09/01/02, the soft tissue sarcoma strata will remain open for new patient accrual. Strata listed in b, c, d, e will be closed to entry). a. soft tissue sarcoma b. bone sarcoma(CLOSED TO ENTRY AS OF 09/01/02) c. Wilms tumor(CLOSED TO ENTRY AS OF 09/01/02) d. lymphoma(CLOSED TO ENTRY AS OF 09/01/02) e. leukemia(CLOSED TO ENTRY AS OF 09/01/02) - Performance status: Zubrod less than 3. Patients with long standing limited mobility requiring the use of a wheelchair will be considered ambulatory for the purpose of this protocol. - Bidimensionally measurable disease radiologically. - No anti-cancer treatment within the past 3 weeks. - ANC greater than or equal to 500; platelets greater than or equal to 50,000; bilirubin less than or equal to 1.5 mg/dl; SGPT less than or equal to 4 x upper normal limit; creatinine less than or equal to 2 x normal. Patients with bone marrow infiltrative disease may be entered irrespective of ANC or platelets. - Minimum life expectancy of greater than or equal to 8 weeks. - Patients may be enrolled after BMT or PSCT if they meet all the above eligibility criteria. Exclusion criteria: - HIV positive. - Serious intercurrent illness, active infections, or second cancer except basal cell carcinoma of the skin or cervical carcinoma in situ. - Eligible for treatment of a higher priority. - Pregnancy. - Grade 3 or 4 sensory or motor dysfunction due to prior vinca alkaloids.
Total Enrollment: 100
Location and Contact Information:
M. D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Cynthia Herzog 713-745-0157
Additional Information:
Study ID Numbers: P99-401;
Study Start Date: June 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038207
Other Soft Tissue Sarcoma Studies:
1. Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
2. Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
3. Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
4. Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
5. In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
Related Studies:
Other Soft Tissue Sarcoma Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies
|
|
|
|
|
|
|
|
